Christine Lovly
Faculty Member
Last active: 9/10/2020

  1. Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition. Paliouras AR, Buzzetti M, Shi L, Donaldson IJ, Magee P, Sahoo S, Leong HS, Fassan M, Carter M, Di Leva G, Krebs MG, Blackhall F, Lovly CM, Garofalo M (2020) EMBO Mol Med 12(7): e11099
    › Primary publication · 32558295 (PubMed) · PMC7338803 (PubMed Central)
  2. Vitamin D3 Metabolites Demonstrate Prognostic Value in -Mutant Lung Adenocarcinoma and Can be Deployed to Oppose Acquired Therapeutic Resistance. Shaurova T, Dy GK, Battaglia S, Hutson A, Zhang L, Zhang Y, Lovly CM, Seshadri M, Goodrich DW, Johnson CS, Hershberger PA (2020) Cancers (Basel) 12(3)
    › Primary publication · 32183160 (PubMed) · PMC7140110 (PubMed Central)
  3. The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA. Disel U, Madison R, Abhishek K, Chung JH, Trabucco SE, Matos AO, Frampton GM, Albacker LA, Reddy V, Karadurmus N, Benson A, Webster J, Paydas S, Cabanillas R, Nangia C, Ozturk MA, Millis SZ, Pal SK, Wilky B, Sokol ES, Gay LM, Soman S, Ganesan S, Janeway K, Stephens PJ, Zhu VW, Ou SI, Lovly CM, Gounder M, Schrock AB, Ross JS, Miller VA, Klempner SJ, Ali SM (2020) Oncologist 25(1): e39-e47
    › Primary publication · 31604903 (PubMed) · PMC6964135 (PubMed Central)
  4. Rapidly fatal pneumonitis from immunotherapy and concurrent SARS-CoV-2 infection in a patient with newly diagnosed lung cancer. Lovly CM, Boyd KL, Gonzalez-Ericsson PI, Lowe CL, Brown HM, Hoffman RD, Sterling BC, Kapp ME, Johnson DB, Kopparapu PR, Iams WT, Warren MA, Noto MJ, Rini BI, Jagasia M, Das SR, Balko JM (2020) medRxiv
    › Primary publication · 32511636 (PubMed) · PMC7276992 (PubMed Central)
  5. N-[F]-Fluoroacetylcrizotinib: A potentially potent and selective PET tracer for molecular imaging of non-small cell lung cancer. Buck JR, Saleh S, Claus T, Lovly C, Hight MR, Nickels ML, Noor Tantawy M, Charles Manning H (2020) Bioorg Med Chem Lett 30(16): 127257
    › Primary publication · 32631505 (PubMed) · PMC7357882 (PubMed Central)
  6. New Approaches to SCLC Therapy: From the Laboratory to the Clinic. Poirier JT, George J, Owonikoko TK, Berns A, Brambilla E, Byers LA, Carbone D, Chen HJ, Christensen CL, Dive C, Farago AF, Govindan R, Hann C, Hellmann MD, Horn L, Johnson JE, Ju YS, Kang S, Krasnow M, Lee J, Lee SH, Lehman J, Lok B, Lovly C, MacPherson D, McFadden D, Minna J, Oser M, Park K, Park KS, Pommier Y, Quaranta V, Ready N, Sage J, Scagliotti G, Sos ML, Sutherland KD, Travis WD, Vakoc CR, Wait SJ, Wistuba I, Wong KK, Zhang H, Daigneault J, Wiens J, Rudin CM, Oliver TG (2020) J Thorac Oncol 15(4): 520-540
    › Primary publication · 32018053 (PubMed) · PMC7263769 (PubMed Central)
  7. Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working Group. Forde PM, Bonomi P, Shaw A, Blumenthal GM, Ferris A, Patel C, Melemed A, Basu Roy U, Ramamoorthy A, Liu Q, Burns T, Gainor JF, Lovly C, Piotrowska Z, Lehman J, Selig W (2020) Clin Lung Cancer 21(4): 295-307
    › Primary publication · 32201247 (PubMed)
  8. COVID-19 and immune checkpoint inhibitors: initial considerations. Sullivan RJ, Johnson DB, Rini BI, Neilan TG, Lovly CM, Moslehi JJ, Reynolds KL (2020) J Immunother Cancer 8(1)
    › Primary publication · 32434790 (PubMed) · PMC7246104 (PubMed Central)
  9. Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion. Tsou TC, Gowen K, Ali SM, Miller VA, Schrock AB, Lovly CM, Reckamp KL (2019) J Thorac Oncol 14(2): e29-e30
    › Primary publication · 30683295 (PubMed)
  10. Small Cell Lung Cancer Transformation as a Mechanism of Resistance to PD-1 Therapy in KRAS-Mutant Lung Adenocarcinoma: A Report of Two Cases. Iams WT, Beckermann KE, Almodovar K, Hernandez J, Vnencak-Jones C, Lim LP, Raymond CK, Horn L, Lovly CM (2019) J Thorac Oncol 14(3): e45-e48
    › Primary publication · 30543839 (PubMed) · PMC6382512 (PubMed Central)